Obesity Market Set for Explosive 27% CAGR Growth by 2036, Fueled by 7 Promising Emerging Therapies | DelveInsight

The seven-major-market obesity therapeutics market, valued at approximately $16 billion in 2025, is projected to grow at a 27% CAGR through 2036 as oral GLP-1s and next-generation multi-agonists broaden treatment options. Novo Nordisk's CagriSema has been filed for U.S. approval, with an FDA decision expected in Q4 2026, after producing 22.7% mean weight loss at 68 weeks in REDEFINE 1 versus 16.1% for Wegovy. Eli Lilly plans an FDA filing for retatrutide in Q1 2027 following Phase III data showing up to 20.8% weight loss at week 80, while multiple competitors advance Phase III programs. Adoption remains constrained by real-world persistence: 65-68% of GLP-1 users discontinue within 12 months and up to 85% by 24 months, driven by cost, coverage, gastrointestinal side effects, and supply limitations.

Analysis

The investable issue is shifting from efficacy leadership to lifetime-value retention. If real-world persistence remains structurally low, headline prescription growth will overstate durable revenue: gross-to-net pressure, restart cycles and payer step-edits will determine net patient-years more than new starts. Oral agents can expand the funnel and reduce manufacturing constraints, but they may also accelerate intra-class switching, limiting the premium pricing and terminal-margin assumptions embedded in LLY and NVO valuations.

LLY appears better positioned near term because its broader cardiometabolic label-expansion program can convert weight-loss demand into reimbursement-supported treatment of comorbidities, raising persistence and reducing cash-pay exposure. NVO's key risk is that a superior injectable efficacy profile alone may not protect share if convenient oral alternatives become the default entry point; the market should focus on refill-at-6/12-month data, discontinuation-adjusted outcomes and formulary tiering rather than cumulative scripts. This creates a likely 1-3 month debate around channel checks and 2027 formulary negotiations, followed by a 6-18 month reset in consensus peak-sales assumptions.

Second-order winners are differentiated obesity developers with evidence in reimbursable comorbidities, particularly ZEAL through liver-disease optionality and AZN through scalable oral delivery, rather than undifferentiated GLP-1 entrants. Conversely, VKTX, ALT and AARD require a demonstrable tolerability, maintenance or disease-specific advantage; merely matching weight loss increasingly has less strategic value as the standard of care commoditizes. The contrarian view is that pipeline breadth is not inherently bearish for leaders: payer access and commercial infrastructure could turn smaller entrants into licensing targets or niche players rather than meaningful share takers.

Key Decisions for Investors

• Maintain a 1-3 month long LLY / short NVO pair, sized beta-neutral: Lilly has better downside protection if payers prioritize outcomes-based reimbursement and comorbidity labels. Target 10-15% relative outperformance; exit if NVO demonstrates superior discontinuation-adjusted persistence or wins material 2027 preferred-formulary positioning.
• Do not chase broad obesity-beta small caps after pipeline headlines. Set a watch alert on ZEAL for liver-outcome and commercialization updates; initiate only if data support fibrosis/MASH differentiation sufficient for payer coverage, not simply incremental weight loss.
• Use AZN as the large-cap oral-GLP-1 optionality vehicle rather than PFE: a successful scalable oral franchise could earn a higher metabolic-growth multiple while AZN's base earnings limit binary trial risk. Reassess following Phase III tolerability, discontinuation and dose-interruption disclosures.
• For NVO, hedge 6-12 month franchise-risk exposure with downside puts around the next major efficacy/persistence readout rather than reducing outright. The thesis is falsified if net price realization and refill persistence offset oral cannibalization, preserving revenue per treated patient despite share dilution.